Leucine-rich repeat-containing protein 19 suppresses colorectal cancer by targeting cyclin-dependent kinase 6/E2F1 and remodeling the immune microenvironment

Figure 7 Leucine-rich repeat-containing 19 inhibits colorectal cancer cell proliferation in vitro and in vivo. A and B: Stable overexpression of leucine-rich repeat-containing 19 (LRRC19) plasmids and vector controls in HT29 and HCT116 cells confirmed by Western blotting; C-F: Anchorage-independent colony formation assays evaluating the effect of LRRC19 overexpression in HT29 and HCT116 cells; G and H: ATP-based cell proliferation assays assessing monolayer cell growth rates; data are shown as the mean ± SD (^bP < 0.05 compared with vector controls); I-K: Xenograft tumor growth in BALB/c nude mice subcutaneously injected with LRRC19-overexpressing or vector-control HCT116 cells. Tumors were excised, photographed, and weighed 4-5 weeks post-injection. Data are presented as the mean ± SD (^bP < 0.05 compared with controls).